|
hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research organisation testing vaccines for infectious and respiratory diseases said it will use its RSV human challenge model to test IN-002 in a randomised, double-blinded trial to assess safety, pharmacokinetics and antiviral activity. The company will use its in-house volunteer recruitment arm, FluCamp, to enrol healthy volunteers for the study. It is expected to start in the second half of 2026 in London, with the majority of revenue recognised in 2026. Chief Executive Officer Yamin Khan said: ‘We previously identified the next generation of vaccines and antivirals, including mucosal-based delivery systems, as being a key growth driver for our challenge trial business. The contract win strengthens our longer term orderbook, adding to visibility into 2026. Inhalon’s IN-002 and its innovative delivery platform could provide a novel way to combat RSV infections. ‘The study is also notable for including three dosing arms - further supporting the trend of biopharma companies looking to obtain greater actionable insights into their candidates earlier to help inform later-stage field trials.’ hVIVO shares closed up 0.1% at 19.27 pence in London on Monday. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
